CD-10 activated prodrug compounds
First Claim
1. A method for treating a tumor comprising contacting the tumor with a therapeutically effective amount of a CD10 cleavable prodrug, wherein said tumor is comprised of one or more target cells which express CD10 for at least a portion of the target cell life cycle, wherein said tumor is selected from the group consisting of B-cell lymphoma, follicular lymphoma, Burkitt lymphoma, and non-Hodgkins'"'"' lymphoma.
2 Assignments
0 Petitions
Accused Products
Abstract
The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the CD10 enzyme. Methods of treatment using the prodrug and methods of designing a prodrug are also disclosed.
29 Citations
23 Claims
- 1. A method for treating a tumor comprising contacting the tumor with a therapeutically effective amount of a CD10 cleavable prodrug, wherein said tumor is comprised of one or more target cells which express CD10 for at least a portion of the target cell life cycle, wherein said tumor is selected from the group consisting of B-cell lymphoma, follicular lymphoma, Burkitt lymphoma, and non-Hodgkins'"'"' lymphoma.
- 12. A method for treating a tumor comprising contacting the tumor with a therapeutically effective amount of a CD10 cleavable prodrug, wherein said tumor is comprised of one or more target cells which express CD10 for at least a portion of the target cell life cycle, wherein said tumor is selected from the group consisting of ocular melanoma and cutaneous melanoma.
-
23. A method for treating a tumor comprising contacting the tumor with a therapeutically effective amount of a CD10 cleavable prodrug, wherein said tumor is comprised of one or more target cells which express CD10 for at least a portion of the target cell life cycle, wherein the CD10 cleavable prodrug comprises:
-
(1) a therapeutic agent capable of entering a target cell, (2) an oligopeptide of the formula (AA)n—
AAP2—
AAP1—
AAP1′
—
(AA)m,wherein; n and m are integers, AAP2 represents isoleucine, AAP1 represents any amino acid, AAP1′
represents any amino acid, andeach AA independently represents an amino acid, (3) a stabilizing group, and (4) optionally, a linker group, wherein the oligopeptide is directly linked to the stabilizing group at a first attachment site of the oligopeptide and the oligopeptide is directly linked to the therapeutic agent or indirectly linked through the linker group to the therapeutic agent at a second attachment site of the oligopeptide, wherein the stabilizing group hinders cleavage of the prodrug by enzymes present in whole blood.
-
Specification